Table 1. Patient characteristics and in vitro treatments.

Pt, patients; No, number; MSC, mesenchymal stromal cell; siRNA, small interfering RNA; CECA, cyclophosphamide, etoposide, carboplatin, and cytosine arabinoside; P/Q, apoptosis in proliferating and quiescent cells; WB, Western blot; % Q cells, percentage of quiescent cells over total CD34⁺ cells; KD, knockdown.

Pt. no.	Source	Blast (%)	*BCR-ABL* status	Treatments and responses	In vitro treatment and assays				% Q cells	Days of coculture with MSC
Pt. no.	Source	Blast (%)	*BCR-ABL* status	Treatments and responses	Cells in which apoptosis was determined		WB/ PCR	Bcl-X_L/ Mcl-1 KD	% Q cells	Days of coculture with MSC
1	PB	91	T315I, E255K	Resistant to imatinib; treated with chemotherapy and dasatinib	P/Q	Bulk/CD34⁺38⁻/ CD34⁺38⁺			9.4	6
2	PB	89	T315I, E255V	Resistant to imatinib, dasatinib, nilotinib, and ponatinib	P/Q	Bulk/CD34⁺38⁻ CD34⁺38⁺	Protein/ RNA	siRNAs	15.9	7
3	PB	83	H396R	Failed imatinib, dasatinib, and nilotinib	P/Q	Bulk/CD34⁺38⁻ CD34⁺38⁺		siRNAs	22.1	10
4a	PB	89	T315I, E255B	Resistant to imatinib, nilotinib, dasatinib, and ponatinib; treated with CECA, ponatinib, and dasatinib		Bulk/CD34⁺38⁻ CD34⁺38⁺	Protein/ RNA	siRNAs
5	PB	80	No mutation	Resistant to imatinib and dasatinib		Bulk	Protein/ RNA
6	BM	93	No mutation	Failed imatinib; treated with nilotinib		Bulk/CD34⁺38⁻ CD34⁺38⁺
4b	PB	62	T315I, E255V	Resistant to imatinib, dasatinib, and ponatinib; treated with nilotinib, decitabine, and dasatinib	P/Q				7.7	6
7	PB	24	No mutation	Resistant to imatinib; treated with nilotinib	P/Q				6.8	8
8	PB	11	No mutation	Resistant to imatinib, dasatinib, nilotinib, and ponatinib; treated with decitabine, dasatinib, and bosutinib	P/Q				14.4	7